- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- Q&A Archive
- The Dean's Perspective
- Department of Pathology
- HMS NEXT
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of Medicine
- Office of Communications & External Relations
- Office of Global Education
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
July 25, 2013
Though existing research has shown that gastric bypass surgery resolves type 2 diabetes, the reason has remained unclear. A research team led by Nicholas Stylopoulos, HMS assistant professor of pediatrics at Boston Children’s Hospital, has identified the small intestine—widely believed to be a passive organ—as the major contributor to the body’s metabolism, based on a study in rats. The report appears in the July 26, 2013, issue of Science.
Weight loss and improved diabetes often go hand in hand, but type 2 diabetes often disappears even before weight loss occurs after gastric bypass. To investigate why this happens, Stylopoulos and his team spent one year studying rats. They observed that after gastric bypass surgery, the small intestine changes the way it processes glucose. The team saw the intestine using and disposing of glucose, thereby regulating blood glucose levels in the rest of the body and helping to eliminate type 2 diabetes.
“We have seen type 2 diabetes resolve in humans after gastric bypass, but have never known why,” said Stylopoulos. “People have been focusing on hormones, fat and muscle, but we have shown in this study that the answer lies somewhere in the small intestine most of the time.”
Gastric bypass surgery, a weight-loss treatment typically reserved for severely obese patients, reroutes food into a small pouch of the stomach and bypasses the rest of the stomach and duodenum. Before gastric bypass, intestines typically do not contain GLUT-1, a specific transporter responsible for removing glucose from circulation and utilizing it within the organ. After gastric bypass, the researchers found that the intestine reprograms itself to contain GLUT-1, taking glucose from circulation and disposing of it, swiftly stabilizing blood glucose levels in the rest of the body.
“Previously, we had not considered the intestine as a major glucose-utilizing organ. We have found this process is exactly what happens after surgery,” said Stylopoulos.
Based on their findings, Stylopoulos and his colleagues found that type 2 diabetes was resolved in 100 percent of the rats that underwent gastric bypass. Sixty-four percent of type 2 diabetes was resolved by the intestine, and the researchers hypothesize that the remaining 36 percent may be due to weight loss or other factors.
These findings pave the way for future investigations of how to create a medical pathway to mimic the intestine’s reprogramming, without the surgery. “With further research, we may find ways to bypass the bypass,” said Stylopoulos. “The results of our study are promising because, unlike the brain and other organs, intestines are easily accessible. Furthermore, since cells in the intestine have such a short lifespan, we can easily study and pharmacologically manipulate them to use glucose, without long-term problems.”
This research was supported with funds from the National Institutes of Health and the Division of Endocrinology, Department of Medicine and the Clinical and Translational Executive Committee at Boston Children’s Hospital.
Adapted from a Boston Children’s Hospital news release.